Fuller & Thaler Asset Management
SUPN icon

Fuller & Thaler Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Fuller & Thaler Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-111
Closed -$3K – 547
2021
Q4 		$3K Sell
111
-182
-62% -$5.52K ﹤0.01% 531
2021
Q3 		$8K Sell
293
-521,967
-100% -$14M ﹤0.01% 501
2021
Q2 		$16.1M Buy
522,260
+203,554
+64% +$6.24M 0.1% 171
2021
Q1 		$8.34M Sell
318,706
-983,309
-76% -$27.5M 0.06% 226
2020
Q4 		$32.8M Buy
1,302,015
+318,620
+32% +$6.86M 0.3% 102
2020
Q3 		$20.5M Buy
983,395
+26,471
+3% +$601K 0.26% 110
2020
Q2 		$22.7M Buy
956,924
+455,532
+91% +$10.1M 0.3% 96
2020
Q1 		$9.02M Sell
501,392
-17,879
-3% -$376K 0.15% 139
2019
Q4 		$12.3M Sell
519,271
-312,976
-38% -$7.6M 0.14% 150
2019
Q3 		$22.9M Buy
832,247
+671,190
+417% +$19.9M 0.27% 112
2019
Q2 		$5.33M Buy
+161,057
New +$5.52M 0.06% 205
2015
Q3 		– Sell
-158
Closed -$3K – 752
2015
Q2 		$3K Buy
+158
New +$2.25K ﹤0.01% 625

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fuller & Thaler Asset Management's SUPN Position: Q1 2022 in Review

Fuller & Thaler Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2022, closing a stake of 111 shares — an estimated $3K sold.

Fuller & Thaler Asset Management first reported a position in SUPN in Q2 2015 and held it in 12 quarters. The position peaked at $32.8M in Q4 2020. 230 funds tracked by Wall St. Rank hold SUPN as of Q1 2022.

  • Fuller & Thaler Asset Management reported no remaining Supernus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 111 Supernus Pharmaceuticals shares in Q1 2022, an estimated $3K.
  • Fuller & Thaler Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 12 quarters.
  • Fuller & Thaler Asset Management's Supernus Pharmaceuticals position peaked at $32.8M in Q4 2020.
  • 230 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2022.

Based on Fuller & Thaler Asset Management's 13F filing for Q1 2022, filed 13 May 2022.